Abstract
BI 1701963 is a small-molecule protein–protein interaction inhibitor, which prevents KRAS activation by binding to the catalytic site of SOS1. This multicentre phase I first-in-human trial is evaluating BI 1701963 as monotherapy (mono tx) or in combination with trametinib in adults with KRAS-mutated solid tumours. Here, we report preliminary results from the mono tx arm, which aims to determine the maximum tolerated dose (MTD) and/or recommended phase II dose of BI 1701963, based on dose-limiting toxicities (DLTs).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
